Fenofibrate-d4

CAT:
804-HY-17356S1
Size:
1 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Fenofibrate-d4 - image 1

Fenofibrate-d4

  • Description:

    Fenofibrate-d4 is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].
  • UNSPSC:

    12352005
  • Target:

    Autophagy; Cytochrome P450; PPAR
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Cardiovascular Disease
  • Solubility:

    10 mM in DMSO
  • Smiles:

    CC (C) (OC1=C ([2H]) C ([2H]) =C (C (C2=CC=C (Cl) C=C2) =O) C ([2H]) =C1[2H]) C (OC (C) C) =O
  • Molecular Formula:

    C20H17D4ClO4
  • Molecular Weight:

    364.86
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78 (3) :639-48.|[3]Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964 (16) 30448-0.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Isotope-Labeled Compounds
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1092484-57-5